Business
GSK to lower drug prices and expand access in US
GSK plc has entered into an agreement with the U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans, including those with asthma and COPD. This voluntary agreement addresses four requests from the U.S. Administration, leading to reduced prices for certain Medicaid drugs and new products with a more balanced pricing approach. GSK will also offer savings of up to 66% on its inhaled respiratory portfolio and other products through a direct purchasing platform. Furthermore, GSK will secure a reserve of albuterol for the U.S. supply chain as part of the President's Strategic Active Pharmaceutical Ingredients Reserve. The agreements, which cover GSK and ViiV Healthcare, provide pricing framework clarity and exclude the companies from s232 tariffs for three years, with detailed terms remaining confidential. Disclaimer*
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 19 December 2025, London UK\n \nGSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans\n \n· Voluntary agreement delivers on all four of President Trump's requests and reduces the cost of medicines for Americans\n· Includes products used to treat the more than 40 million patients in the U.S. who suffer from respiratory conditions such as asthma and COPD\n· Builds on GSK's decades-long commitment to make products accessible worldwide to those who need them\n \n\nGSK plc (LSE/NYSE: GSK) announced that it has entered into an agreement with the U.S. Administration to lower the cost of prescription medicines for American patients, including GSK's broad respiratory portfolio which is used to treat the more than 40 million Americans who suffer from respiratory conditions such as asthma and COPD.\n \nThe agreement delivers on all four actions requested by President Trump in his July 31st letter. As part of the agreement, GSK will lower the price of certain medicines in Medicaid and will launch new products with a more balanced pricing approach which recognises the value of innovation across developed nations.\n \nBuilding on GSK's ongoing global commitment to responsible pricing, the Company will also make most of its inhaled respiratory portfolio and other products available to patients on a direct purchasing platform that will offer savings of up to 66%.\n \nAs part of the President's Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), GSK will further support the resilience of the U.S. supply chain for critical medicines by securing for the U.S. a reserve of albuterol (also known as salbutamol), the active ingredient used in many inhalers to relieve the symptoms of asthma and COPD.\n \nThe agreements entered into cover both GSK and ViiV Healthcare. The agreements provide clarity to both companies on the future US pricing framework, and exclude GSK and ViiV from s232 tariffs for 3 years. The detailed terms of the agreements remain confidential.\n \nGSK CEO Emma Walmsley said: \"Today's announcement builds on GSK's strong track record of increasing\naccess and improving the affordability of its medicines worldwide, including an ongoing commitment to responsible pri...